瑞格列奈药代动力学特征及有关基因多态性对其药代和药物相互作用的影响

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (4): 468-473.

瑞格列奈药代动力学特征及有关基因多态性对其药代和药物相互作用的影响

孙旭^1,2, 袁钊¹, 温金华¹, 熊玉卿¹

¹南昌大学医学院临床药理研究所,南昌 330006, 江西;
²中国食品药品检定研究院国家药物安全评价监测中心,北京 100176

收稿日期:2011-02-10 修回日期:2011-03-22 发布日期:2011-06-22
通讯作者: 熊玉卿,女,教授,博士生导师,研究方向:临床药理学与药物代谢动力学。Tel: 0791-6361081 E-mail: xiongyuqing2009@hotmail.com
作者简介:孙旭,男,硕士研究生,研究方向:临床药理学。Tel: 0791-6361081 E-mail: SunXu-513@163.com
基金资助:
国家“十一五”科技重大专项“建立新药研发安全监测信息化技术平台”子课题“构建I期临床试验研究和风险监测的信息化监管技术平台”(2009ZX09309-003-02)

Study on pharmacokinetic features of Repaglinide and the influence of genetic polymorphisms on its pharmacokinetics and drug interactions

SUN Xu^1,2,YUAN Zhao¹,WEN Jin-hua¹,XIONG Yu-qing¹

¹Institute of Clinical Pharmacology, Medical College of Nanchang University, Nanchang 330006,Jiangxi,China;
²National Center for Safety Evaluation of Drugs , Research Institute of China Food and Drug,Beijing 100176,China

Received:2011-02-10 Revised:2011-03-22 Published:2011-06-22

摘要/Abstract

摘要： 瑞格列奈是一种具有氨基酸结构的非磺脲类促胰岛素分泌的口服降糖药,降血糖作用快而短,模拟胰岛素生理性分泌,主要用于控制高血糖,同时减少低血糖的发生。本文将对瑞格列奈的药代动力学特征、基因组学研究进展、药物相互作用作一综述。以期为指导瑞格列奈的临床用药打下坚实的理论基础,确保临床用药的安全性和有效性,真正实现临床上的个体化给药。

关键词: 瑞格列奈, 药代动力学特征, 基因多态性, 个体化给药

Abstract: Repaglinide is a novel non-sulfonylurea oral hypoglycemic agent by stimulating insulin secretion, with a structure of amino acid profile.Its action occurs rapidly and sustains shortly.By simulating the physiology secretion of insulin, it majors in controlling hyperglycemia and reduces the incident of hypoglycemia.In this paper,we will give a review about the pharmacokinetic features, genomics research progress, drug interaction of repaglinide,in order to lay down a solid theory foundation for the guidance in clinical usage of repaglinide, ensure the safety and effectiveness of clinical usage, achieving individualized therapy in its true sense.

Key words: Repaglinide, Pharmacokinetic feature, Genetic polymorphism, Individualized therapy

中图分类号:

R969

孙旭, 袁钊, 温金华, 熊玉卿. 瑞格列奈药代动力学特征及有关基因多态性对其药代和药物相互作用的影响[J]. 中国临床药理学与治疗学, 2011, 16(4): 468-473.

SUN Xu,YUAN Zhao,WEN Jin-hua,XIONG Yu-qing. Study on pharmacokinetic features of Repaglinide and the influence of genetic polymorphisms on its pharmacokinetics and drug interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 468-473.

参考文献

[1] Owens DR. Repaglinide - prandial glucose regulator: a new class of oral antidiabetic drugs[J]. Diabet Med, 1999,15(4): S28-S36.
[2] 杨华章,陈亮,崔炎棠. 降糖新药瑞格列奈的研究进展[J]. 中国实用内科杂志, 2004, 20(4): 253-254.
[3] 胡晋红, 李珍, 刘晓东, 等. 国产与进口降糖药瑞格列奈片的生物等效性研究[J]. 第二军医大学学报, 2001, 22( 5): 432-434.
[4] Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics[J]. Clin Pharmacol Ther, 2005, 77(6): 468-478.
[5] Zair ZM, Eloranta JJ, Stieger B, et al. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney [J]. Pharmacogenomics, 2008, 9(5): 597-624.
[6] Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties[J]. Pflugers Arch, 2004,447(5): 653-665.
[7] Niemi M. Role of OATP transporters in the disposition of drugs[J]. Pharmacogenomics, 2007, 8(7): 787-802.
[8] Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP2C(SLC21A6) and OATP2B(SLC21A9) : allele frequencies in the Japanese population and functional analysis[J]. J Pharm Acol Exp Ther, 2002,302 (2) :804-813.
[9] Niemi M, Schaeffeler E , Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide2C (OATP2C , SLCO1B1) [J].Pharmacogenetics, 2004,14 (7) :429-440.
[10] Kim EY, Cho DY, Shin HJ, et al. Duplex pyrosequencing assay of the 388A > Gand 521T> C SLCO1B1 polymorphisms in three Asian populations [J]. Clin Chim Acta, 2008,388 (1P2) :68-72.
[11] Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP2C) variants, SLCO1B1^*5 , SLCO1B1^*15 and SLCO1B1^*15 +C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005,15 (7) :513-522.
[12] Kalliokoski A , Backman JT, Neuvonen PJ , et al. Effects of the SLCO1B1^*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide [J].Pharmacogenet Genomics , 2008 ,18 (11) :937-942.
[13] Deng JW, Song IS , Shin HJ , et al. The effect of SL2CO1B1^*15 on the disposition of pravastatin and pitavastatin is substrate dependent : the contribution of transporting activity changes by SLCO1B1*15 [J]. Pharmacogenet Genomics, 2008,18 (5) :424-433.
[14] Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. J Clin Pharmacol, 2008, 48 (3) : 311-321.
[15] Kalliokoski A , Backman JT, Kurkinen KJ , et al. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism[J]. Clin Pharmacol Ther, 2008,84 (4) :488-496.
[16] 阳国平, 宋敏, 谭鸿毅, 等.有机阴离子转运多肽1B1(OATP1B1)遗传多态性对瑞格列奈药动学的影响[J].中国临床药理学与治疗学, 2009, 14(9): 990-994.
[17] Bidstrup TB, Bjnsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide[J].Br J Clin Pharmaco, 2003, l56: 305-314.
[18] Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide's pharmacolinetics[J]. Pharmacology,2010,85(6):357-364.
[19] Niemi M, Leathart J B, Neuvonen M, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide[J].Clin Pharmacol Ther, 2003, 74(4): 380-387.
[20] Bidstrup TB, Damkier P, Olsen AK, et al. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokineties of repaglinide[J]. Br J Clin Pharmacol, 2006, 61(1): 49-57.
[21] Rodríguez-Antona C, Niemi M, Backman JT, et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism[J]. Pharmacogenomics J, 2007, 8(4): 268-277.
[22] Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor l[J].Diabetes, 2002, 51(9): 2789-2795.
[23] Hansen AM, Hansen JB, Carr RD, et al. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP)channels[J].Br J Pharmacol, 2005, 144(4): 551-557.
[24] Tanja BB, Nicolaj S, Per Damkier, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide[J]. Eur J Clin Pharmacol,2004, 60(2): 109-114.
[25] Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil,itraconazole,and their combination on the pharmacokinetics and pharmacodynamics of repaglinide:potentially hazardous interaction between gemfibrozil and regaplinide[J]. Diabetoligia, 2003, 46(3): 347-351.
[26] Ashfield R, Gribble FM, Ashcroft SJ, et al. Identfication of the high-affinity tolbutamide site on the SURI subunit of the K(ATP)channel[J].Diabetes, 1999, 48(6): 1341-1347.
[27] Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide[J]. Clin Pharmacol Ther, 2005, 78(4): 388-399.
[28] Kajosaari LI, Jaakkola T, Neuvonen PJ, et al. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide[J]. Eur J Clin Pharmacol, 2006, 62(3): 217-223.
[29] Niemi M, Kajosaari LI, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasmaconcentrations of repaglinide in healthy subjects[J].Br J Clin Pharmacol, 2003, 57(4): 441-447.